{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:46:06Z","timestamp":1793947566998,"version":"4.8.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.phrs.2024.107234","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T16:43:21Z","timestamp":1716914601000},"page":"107234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["PROTACs targeting androgen receptor signaling: Potential therapeutic agents for castration-resistant prostate cancer"],"prefix":"10.1016","volume":"205","author":[{"given":"Yulu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annan","family":"Ming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenmin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqing","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.phrs.2024.107234_bib1","first-page":"5","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA: a Cancer J. Clin."},{"key":"10.1016\/j.phrs.2024.107234_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-319-99286-0_7","article-title":"Castration-resistant prostate cancer: mechanisms, targets and treatment","author":"Mansinho","year":"2018","journal-title":"Adv. Exp. Med. Biol. 1096"},{"issue":"3","key":"10.1016\/j.phrs.2024.107234_bib3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pharmthera.2013.07.003","article-title":"Androgen receptors in hormone-dependent and castration-resistant prostate cancer","volume":"140","author":"Shafi","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2024.107234_bib4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","article-title":"Treatment of advanced prostate cancer","volume":"70","author":"Teo","year":"2019","journal-title":"Annu. Rev. Med."},{"issue":"15","key":"10.1016\/j.phrs.2024.107234_bib5","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/ajhp\/zxac105","article-title":"Targeting the androgen receptor signaling pathway in advanced prostate cancer","volume":"79","author":"Chung","year":"2022","journal-title":"Am. J. Health Syst. Pharm. JHP: Off. J. Am. Soc. Health-Syst. Pharm."},{"issue":"9","key":"10.1016\/j.phrs.2024.107234_bib6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.steroids.2013.04.012","article-title":"Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer","volume":"78","author":"Culig","year":"2013","journal-title":"Steroids"},{"issue":"9","key":"10.1016\/j.phrs.2024.107234_bib7","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1021\/cr020456u","article-title":"Chemistry and structural biology of androgen receptor","volume":"105","author":"Gao","year":"2005","journal-title":"Chem. Rev."},{"key":"10.1016\/j.phrs.2024.107234_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.06.006","article-title":"Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance","volume":"518","author":"Jamroze","year":"2021","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.phrs.2024.107234_bib9","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1210\/mend-5-10-1396","article-title":"Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization","volume":"5","author":"Jenster","year":"1991","journal-title":"Mol. Endocrinol."},{"issue":"1-2","key":"10.1016\/j.phrs.2024.107234_bib10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.mce.2011.07.004","article-title":"Post-translational modification of the androgen receptor","volume":"352","author":"Gioeli","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"issue":"3","key":"10.1016\/j.phrs.2024.107234_bib11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ajur.2019.11.001","article-title":"Posttranslational regulation of androgen dependent and independent androgen receptor activities in prostate cancer","volume":"7","author":"Wen","year":"2020","journal-title":"Asian J. Urol."},{"key":"10.1016\/j.phrs.2024.107234_bib12","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/bs.vh.2023.01.001","article-title":"The androgen receptor","author":"Van-Duyne","year":"2023","journal-title":"Vitam. Horm. 123"},{"issue":"4","key":"10.1016\/j.phrs.2024.107234_bib13","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0094-0143(21)00928-9","article-title":"PSA and PAP as immunohistochemical markers in prostate cancer","volume":"20","author":"Epstein","year":"1993","journal-title":"Urol. Clin. North Am."},{"key":"10.1016\/j.phrs.2024.107234_bib14","doi-asserted-by":"crossref","first-page":"14388","DOI":"10.1038\/ncomms14388","article-title":"Structure of the homodimeric androgen receptor ligand-binding domain","volume":"8","author":"Nadal","year":"2017","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.phrs.2024.107234_bib15","doi-asserted-by":"crossref","first-page":"12496","DOI":"10.3390\/ijms140612496","article-title":"Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer","volume":"14","author":"Lallous","year":"2013","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.phrs.2024.107234_bib16","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ccr.2010.04.027","article-title":"Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor","volume":"17","author":"Andersen","year":"2010","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.phrs.2024.107234_bib17","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.molcel.2022.03.035","article-title":"Allosteric interactions prime androgen receptor dimerization and activation","volume":"82","author":"Wasmuth","year":"2022","journal-title":"Mol. Cell"},{"issue":"7","key":"10.1016\/j.phrs.2024.107234_bib18","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1021\/ml300090x","article-title":"Imidazo[1,2-a]pyridines that directly interact with hepatitis C NS4B: initial preclinical characterization","volume":"3","author":"Shotwell","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.phrs.2024.107234_bib19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/CU9.0000000000000120","article-title":"Androgen receptor signaling-mitochondrial DNA-oxidative phosphorylation: a critical triangle in early prostate cancer","volume":"16","author":"Sakellakis","year":"2022","journal-title":"Curr. Urol."},{"issue":"5","key":"10.1016\/j.phrs.2024.107234_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cells11050898","article-title":"Androgen receptor-mediated transcription in prostate cancer","volume":"11","author":"\u00d6zturan","year":"2022","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.phrs.2024.107234_bib21","first-page":"366","article-title":"Mechanisms and targeting of proteosome-dependent androgen receptor degradation in prostate cancer","volume":"10","author":"Fang","year":"2022","journal-title":"Am. J. Clin. Exp. Urol."},{"issue":"10","key":"10.1016\/j.phrs.2024.107234_bib22","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1021\/acschembio.7b00485","article-title":"Assessing different E3 ligases for small molecule induced protein ubiquitination and degradation","volume":"12","author":"Ottis","year":"2017","journal-title":"ACS Chem. Biol."},{"issue":"14","key":"10.1016\/j.phrs.2024.107234_bib23","first-page":"993","article-title":"MDM2, an introduction","volume":"1","author":"Iwakuma","year":"2003","journal-title":"Mol. Cancer Res.: MCR"},{"issue":"2","key":"10.1016\/j.phrs.2024.107234_bib24","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a008730","article-title":"Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation","volume":"5","author":"Silke","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.phrs.2024.107234_bib25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1101\/sqb.2005.70.001","article-title":"The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing","volume":"70","author":"Kaelin","year":"2005","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"10.1016\/j.phrs.2024.107234_bib26","first-page":"9130608","article-title":"Cereblon: a protein crucial to the multiple functions of immunomodulatory drugs as well as cell metabolism and disease generation","author":"Shi","year":"2017","journal-title":"J. Immunol. Res. 2017"},{"issue":"15","key":"10.1016\/j.phrs.2024.107234_bib27","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.phrs.2024.107234_bib28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11064-022-03722-w","article-title":"Scrutinizing the therapeutic potential of PROTACs in the management of Alzheimer's disease","volume":"48","author":"Bhatia","year":"2023","journal-title":"Neurochem. Res."},{"issue":"1","key":"10.1016\/j.phrs.2024.107234_bib29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13045-022-01258-8","article-title":"A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.phrs.2024.107234_bib30","article-title":"Targeting androgen receptor degradation with PROTACs from bench to bedside","volume":"158","author":"Jia","year":"2023","journal-title":"Biomed. Pharmacother. = Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.phrs.2024.107234_bib31","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.cbpa.2008.07.001","article-title":"Nuclear receptor drug discovery","volume":"12","author":"Chen","year":"2008","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"24","key":"10.1016\/j.phrs.2024.107234_bib32","doi-asserted-by":"crossref","first-page":"16128","DOI":"10.1021\/acs.jmedchem.2c01487","article-title":"A comprehensive overview of small-molecule androgen receptor degraders: recent progress and future perspectives","volume":"65","author":"Ha","year":"2022","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.phrs.2024.107234_bib33","doi-asserted-by":"crossref","first-page":"T39","DOI":"10.1530\/ERC-21-0118","article-title":"Second-generation hormonotherapy in prostate cancer and bone microenvironment","volume":"28","author":"Bouleftour","year":"2021","journal-title":"Endocr. -Relat. Cancer"},{"issue":"6","key":"10.1016\/j.phrs.2024.107234_bib34","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1177\/106002809002400612","article-title":"Flutamide: an antiandrogen for advanced prostate cancer","volume":"24","author":"Goldspiel","year":"1990","journal-title":"DICP: Ann. Pharmacother."},{"issue":"5-6","key":"10.1016\/j.phrs.2024.107234_bib37","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0960-0760(94)90131-7","article-title":"Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase\/C17-20 lyase)","volume":"50","author":"Barrie","year":"1994","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"2","key":"10.1016\/j.phrs.2024.107234_bib38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bju.13123","article-title":"Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer","volume":"117","author":"Schalken","year":"2016","journal-title":"BJU Int."},{"key":"10.1016\/j.phrs.2024.107234_bib39","unstructured":"Darolutamide, LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD), 2012."},{"issue":"1","key":"10.1016\/j.phrs.2024.107234_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94707-2","article-title":"Conformational dynamics of androgen receptors bound to agonists and antagonists","volume":"11","author":"Gim","year":"2021","journal-title":"Sci. Rep."},{"issue":"17","key":"10.1016\/j.phrs.2024.107234_bib41","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1038\/onc.2011.401","article-title":"Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer","volume":"31","author":"Urbanucci","year":"2012","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.phrs.2024.107234_bib42","doi-asserted-by":"crossref","first-page":"R146","DOI":"10.1530\/EC-17-0118","article-title":"Clinical relevance of androgen receptor alterations in prostate cancer","volume":"6","author":"Jernberg","year":"2017","journal-title":"Endocr. Connect."},{"issue":"2","key":"10.1016\/j.phrs.2024.107234_bib43","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41391-020-00309-w","article-title":"Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide","volume":"24","author":"Del Re","year":"2021","journal-title":"Prostate Cancer prostatic Dis."},{"key":"10.1016\/j.phrs.2024.107234_bib44","doi-asserted-by":"crossref","unstructured":"T. Neklesa, L.B. Snyder, R.R. Willard, N. Vitale, K. Raina, J. Pizzano, D. Gordon, M. Bookbinder, J. Macaluso, H. Dong, Z. Liu, C. Ferraro, G. Wang, J. Wang, C.M. Crews, J. Houston, A.P. Crew, I. Taylor, Caterina, ARV-110: An androgen receptor PROTAC degrader for prostate cancer, Proceedings of the American Association for Cancer Research Annual Meeting 2018, Chicago, IL. Philadelphia (PA), 2018.","DOI":"10.1158\/1538-7445.AM2018-5236"},{"key":"10.1016\/j.phrs.2024.107234_bib45","doi-asserted-by":"crossref","unstructured":"L. Snyder, S.H. Lee, T.K. Neklesa, X. Chen, H. Dong, C. Ferraro, D.A. Gordon, J. Macaluso, J. Pizzano, J. Wang, R.R. Willard, N. Vitale, R. Peck, M.D. Moore, C.M. Crews, J. Houston, A.P. Crew, I. Taylor, Discovery of ARV-766, an androgen receptor degrading PROTAC\u00ae for the treatment of men with metastatic castration resistant prostate cancer Proceedings of the American Association for Cancer Research Annual Meeting 2023, Orlando, FL. Philadelphia (PA), 2023.","DOI":"10.1158\/1538-7445.AM2023-ND03"},{"key":"10.1016\/j.phrs.2024.107234_bib46","series-title":"Arvinas Announces Interim Data from the ARV-766 Phase 1\/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations","author":"Boyle","year":"2023"},{"issue":"1","key":"10.1016\/j.phrs.2024.107234_bib47","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s43556-022-00112-0","article-title":"An overview of PROTACs: a promising drug discovery paradigm","volume":"3","author":"Liu","year":"2022","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.phrs.2024.107234_bib48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ctrv.2015.12.003","article-title":"AR-V7 and prostate cancer: the watershed for treatment selection?","volume":"43","author":"Ciccarese","year":"2016","journal-title":"Cancer Treat. Rev."},{"issue":"6","key":"10.1016\/j.phrs.2024.107234_bib49","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1210\/en.2017-00109","article-title":"Androgen receptor rearrangement and splicing variants in resistance to endocrine therapies in prostate cancer","volume":"158","author":"Ho","year":"2017","journal-title":"Endocrinology"},{"key":"10.1016\/j.phrs.2024.107234_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128448","article-title":"Design, synthesis, and biological evaluation of phenyl thiazole-based AR-V7 degraders","volume":"55","author":"Bhumireddy","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"14","key":"10.1016\/j.phrs.2024.107234_bib51","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1073\/pnas.0401123101","article-title":"Structural basis of androgen receptor binding to selective androgen response elements","volume":"101","author":"Shaffer","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.phrs.2024.107234_bib52","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/1535-7163.MCT-20-0417","article-title":"Effects of MTX-23, a novel PROTAC of androgen receptor splice variant-7 and androgen receptor, on CRPC resistant to second-line antiandrogen therapy","volume":"20","author":"Lee","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.phrs.2024.107234_bib53","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1039\/C8NR09849B","article-title":"Polyethyleneimine-assisted one-pot synthesis of quasi-fractal plasmonic gold nanocomposites as a photothermal theranostic agent","volume":"11","author":"Mulens-Arias","year":"2019","journal-title":"Nanoscale"},{"issue":"28","key":"10.1016\/j.phrs.2024.107234_bib54","article-title":"De Novo design of an androgen receptor DNA binding domain-targeted peptide PROTAC for prostate cancer therapy","volume":"9","author":"Ma","year":"2022","journal-title":"Adv. Sci. (Weinh., Baden. -Wurtt., Ger. )"},{"key":"10.1016\/j.phrs.2024.107234_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104500","article-title":"Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer","volume":"90","author":"Hung","year":"2023","journal-title":"EBioMedicine"},{"issue":"16","key":"10.1016\/j.phrs.2024.107234_bib56","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.1021\/acs.jmedchem.3c00585","article-title":"Discovery of BWA-522, a first-in-class and orally bioavailable PROTAC degrader of the androgen receptor targeting N-terminal domain for the treatment of prostate cancer","volume":"66","author":"Zhang","year":"2023","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2024.107234_bib57","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1530\/JME-11-0018","article-title":"Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target","volume":"47","author":"Shiota","year":"2011","journal-title":"J. Mol. Endocrinol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107234_bib58","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nm972","article-title":"Molecular determinants of resistance to antiandrogen therapy","volume":"10","author":"Chen","year":"2004","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.phrs.2024.107234_bib59","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1080\/14789450.2021.2007766","article-title":"Protein lysine acetylation and its role in different human pathologies: a proteomic approach","volume":"18","author":"Morales-Tarr\u00e9","year":"2021","journal-title":"Expert Rev. Proteom."},{"issue":"5","key":"10.1016\/j.phrs.2024.107234_bib60","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1021\/acs.jmedchem.0c01487","article-title":"Targeting bromodomain and extraterminal proteins for drug discovery: from current progress to technological development","volume":"64","author":"Tang","year":"2021","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.phrs.2024.107234_bib61","doi-asserted-by":"crossref","first-page":"13141","DOI":"10.1074\/jbc.R700001200","article-title":"The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation","volume":"282","author":"Wu","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.phrs.2024.107234_bib62","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrd4286","article-title":"Targeting bromodomains: epigenetic readers of lysine acetylation, Nature reviews","volume":"13","author":"Filippakopoulos","year":"2014","journal-title":"Drug Discov."},{"issue":"1","key":"10.1016\/j.phrs.2024.107234_bib63","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1158\/2159-8290.CD-17-0605","article-title":"BET proteins as targets for anticancer treatment","volume":"8","author":"Stathis","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2024.107234_bib64","article-title":"Post-translational modifications of BRD4: therapeutic targets for tumor","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2024.107234_bib65","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/13543784.2023.2186851","article-title":"Role of bromodomain and extraterminal (BET) proteins in prostate cancer","volume":"32","author":"Mandl","year":"2023","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"26","key":"10.1016\/j.phrs.2024.107234_bib66","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.1521738113","article-title":"PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer","volume":"113","author":"Raina","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.phrs.2024.107234_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15384047.2022.2125748","article-title":"BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes","volume":"23","author":"Ma","year":"2022","journal-title":"Cancer Biol. Ther."},{"issue":"11","key":"10.1016\/j.phrs.2024.107234_bib68","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.tibs.2005.09.005","article-title":"Mammalian cyclin-dependent kinases","volume":"30","author":"Malumbres","year":"2005","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.phrs.2024.107234_bib69","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2018.09.014","article-title":"Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer","volume":"438","author":"Russo","year":"2018","journal-title":"Cancer Lett."},{"issue":"43","key":"10.1016\/j.phrs.2024.107234_bib70","doi-asserted-by":"crossref","first-page":"15969","DOI":"10.1073\/pnas.0604193103","article-title":"Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1","volume":"103","author":"Chen","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.phrs.2024.107234_bib71","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/emboj.2010.337","article-title":"The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin\/proteasome process","volume":"30","author":"Chymkowitch","year":"2011","journal-title":"EMBO J."},{"issue":"54","key":"10.1016\/j.phrs.2024.107234_bib72","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1039\/C7CC03879H","article-title":"Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)","volume":"53","author":"Robb","year":"2017","journal-title":"Chem. Commun. (Camb., Engl. )"},{"key":"10.1016\/j.phrs.2024.107234_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111952","article-title":"Development of selective mono or dual PROTAC degrader probe of CDK isoforms","volume":"187","author":"Zhou","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"49","key":"10.1016\/j.phrs.2024.107234_bib74","doi-asserted-by":"crossref","first-page":"20980","DOI":"10.1073\/pnas.1012525107","article-title":"Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas","volume":"107","author":"Sneeringer","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6113","key":"10.1016\/j.phrs.2024.107234_bib75","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1227604","article-title":"EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent","volume":"338","author":"Xu","year":"2012","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.phrs.2024.107234_bib76","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/ijc.32118","article-title":"Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer","volume":"145","author":"Liu","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.phrs.2024.107234_bib77","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1158\/0008-5472.CAN-16-1949","article-title":"Polycomb-Mediated Disruption of an Androgen Receptor Feedback Loop Drives Castration-Resistant Prostate Cancer","volume":"77","author":"Fong","year":"2017","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.phrs.2024.107234_bib78","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: a novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2024.107234_bib79","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41556-022-00850-x","article-title":"EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis","volume":"24","author":"Wang","year":"2022","journal-title":"Nat. Cell Biol."},{"issue":"19","key":"10.1016\/j.phrs.2024.107234_bib80","doi-asserted-by":"crossref","first-page":"10929","DOI":"10.1093\/nar\/gkac861","article-title":"A cryptic transactivation domain of EZH2 binds AR and AR's splice variant, promoting oncogene activation and tumorous transformation","volume":"50","author":"Wang","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.phrs.2024.107234_bib81","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/cas.14840","article-title":"The noncanonical role of EZH2 in cancer","volume":"112","author":"Huang","year":"2021","journal-title":"Cancer Sci."},{"issue":"2","key":"10.1016\/j.phrs.2024.107234_bib82","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1097-2765(03)00039-X","article-title":"SWI\/SNF unwraps, slides, and rewraps the nucleosome","volume":"11","author":"Kassabov","year":"2003","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.phrs.2024.107234_bib83","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/ng.2628","article-title":"Proteomic and bioinformatic analysis of mammalian SWI\/SNF complexes identifies extensive roles in human malignancy","volume":"45","author":"Kadoch","year":"2013","journal-title":"Nat. Genet."},{"issue":"7765","key":"10.1016\/j.phrs.2024.107234_bib84","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41586-019-1347-4","article-title":"Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer","volume":"571","author":"Parolia","year":"2019","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.phrs.2024.107234_bib85","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cell.2018.05.036","article-title":"Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing","volume":"174","author":"Viswanathan","year":"2018","journal-title":"Cell"},{"issue":"7893","key":"10.1016\/j.phrs.2024.107234_bib86","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-021-04246-z","article-title":"Targeting SWI\/SNF ATPases in enhancer-addicted prostate cancer","volume":"601","author":"Xiao","year":"2022","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.phrs.2024.107234_bib87","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2322563121","article-title":"Development of an orally bioavailable mSWI\/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer","volume":"121","author":"He","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"13","key":"10.1016\/j.phrs.2024.107234_bib88","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/onc.2012.191","article-title":"Genome-wide mechanisms of Smad binding","volume":"32","author":"Morikawa","year":"2013","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.phrs.2024.107234_bib89","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/cncr.31161","article-title":"Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC)","volume":"124","author":"Pal","year":"2018","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.phrs.2024.107234_bib90","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1093\/nar\/gkad043","article-title":"SMAD3 promotes expression and activity of the androgen receptor in prostate cancer","volume":"51","author":"Jeon","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2024.107234_bib91","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bcp.2016.07.017","article-title":"New strategy for renal fibrosis: Targeting Smad3 proteins for ubiquitination and degradation","volume":"116","author":"Wang","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107234_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114838","article-title":"A bibliometric analysis of PROTAC from 2001 to 2021","volume":"244","author":"Li","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.phrs.2024.107234_bib93","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16030663","article-title":"Insight into recent advances in degrading androgen receptor for castration-resistant prostate cancer","volume":"16","author":"Chen","year":"2024","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.phrs.2024.107234_bib94","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28093698","article-title":"PROTACs in the management of prostate cancer","volume":"28","author":"Yedla","year":"2023","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.phrs.2024.107234_bib95","doi-asserted-by":"crossref","first-page":"7133","DOI":"10.1038\/s41467-022-34807-3","article-title":"DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.phrs.2024.107234_bib96","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22042124","article-title":"An overview of next-generation androgen receptor-targeted therapeutics in development for the treatment of prostate cancer","volume":"22","author":"Mohler","year":"2021","journal-title":"Int. J. Mol. Sci."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824001798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824001798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T21:53:16Z","timestamp":1718833996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661824001798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":94,"alternative-id":["S1043661824001798"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107234","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PROTACs targeting androgen receptor signaling: Potential therapeutic agents for castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107234","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107234"}}